Current Report Filing (8-k)
November 12 2019 - 3:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported)
November 12, 2019
INTEC PHARMA LTD.
(Exact name of registrant as specified in
its charter)
Israel
|
001-37521
|
N/A
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
12 Hartom St.
Har Hotzvim
|
|
|
|
Jerusalem, Israel
|
9777512
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
+ 972-2-586-4657
|
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report)
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
Ordinary Shares, no, par value
|
|
NTEC
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 2.02.
|
Results of Operation and Financial Condition.
|
On November 12, 2019, Intec
Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the third
quarter ended September 30, 2019. The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference herein in its entirety.
The information included
in this Item 2.02 of Current Report on Form 8-K, including the attached Exhibit 99.1, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general
incorporation language in any such filing, except as expressly set forth by specific reference in such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
1
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: November 12, 2019
|
INTEC PHARMA LTD.
|
|
|
|
By:
|
/s/ Nir Sassi
|
|
|
Nir Sassi
|
|
|
Chief Financial Officer
|
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Intec Parent Inc (NASDAQ): 0 recent articles
More Intec Pharma Ltd. News Articles